BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Start-Up Veteran Joins Atlanta Catheter Therapies as CEO


3/12/2010 6:51:48 AM

ATLANTA, GA--(Marketwire - 03/12/10) - Paul J. Fitzpatrick has joined Atlanta Catheter Therapies, Inc. (ACT) (http://www.atlcath.com) as Chief Executive Officer. The experienced start-up expert will guide the company through development and commercialization of innovative catheter technologies for the treatment of vascular disease and restenosis.

Atlanta Catheter Therapies is an early stage research and development medical device company with an innovative and targeted portfolio of catheter technologies for the treatment of vascular disease and restenosis. ACT has developed a revolutionary drug delivery device for the treatment of restenosis (re-blockage of blood vessels) and is developing devices for endovascular debulking (clearing of blocked blood vessels).

"Our focus at ACT is on substantially improving patient care and lowering healthcare costs related to the treatment of vascular disease and restenosis," said Fitzpatrick. "Our role in product development includes design, IP patent filing, engineering, working prototyping, bench testing, animal testing, and regulatory approvals.

"Once the device is ready for human trials, manufacturing, sales and distribution, ACT will out-license or sell each device technology to a strategic partner," he added.

With 24 years of diverse, entrepreneurial business and healthcare experience, Fitzpatrick has a proven track record of delivering results, including running PJ Fitzpatrick Executive Advisory Group, which provides interim and fractional C-level and board engagements to early stage and small companies.

Fitzpatrick has completed over 20 merger and acquisition transactions with a combined value in excess of $100 million, and has been involved with numerous start-ups, turnarounds, roll-ups and integration of acquired companies with a range of public, private and venture-backed financing. With an in-depth knowledge of medical devices, clinical and patient care services, developing strategic alliances, multi-site and multi-state state operations, education and international recruiting and staffing, Fitzpatrick brings a rich skill set and knowledge base to his role with ACT.

Learn more at www.atlcath.com.

Media Contact: Lynn Hood Email Contact 678-427-5040 Company Contact: Paul Fitzpatrick Email Contact 770-321-8439

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->